(Q37784674)

23 August 2017

title

Recommendations for visual evaluations of patients treated with vigabatrin (English)

1 reference

23 August 2017

Robert C. Sergott

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20811279

5 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20811279

5 July 2024

publication date

1 November 2010

1 reference

full work available at URL

23 August 2017

https://journals.lww.com/10.1097/ICU.0b013e32833f0085

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Current Opinion in Ophthalmology

5 July 2024

published in

1 reference

23 August 2017

volume

21

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

442-446

1 reference

23 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group

5 July 2024

2

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Vigabatrin Protocol 024 Investigative Cohort

5 July 2024

3

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.

5 July 2024

4

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy

5 July 2024

5

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups

5 July 2024

6

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms

5 July 2024

7

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Vigabatrin in infantile spasms

5 July 2024

8

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis

5 July 2024

9

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Randomized trial of vigabatrin in patients with infantile spasms

5 July 2024

10

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome

5 July 2024

11

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Visual field defects associated with vigabatrin therapy

5 July 2024

13

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Characteristics of a unique visual field defect attributed to vigabatrin

5 July 2024

14

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings

5 July 2024

15

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings

5 July 2024

16

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin

5 July 2024

17

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy

5 July 2024

18

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children

5 July 2024

19

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction

5 July 2024

20

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?

5 July 2024

21

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity

5 July 2024

22

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Severe persistent visual field constriction associated with vigabatrin

5 July 2024

23

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Characterization of vigabatrin‐associated optic atrophy

5 July 2024

24

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

5 July 2024

25

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation

5 July 2024

26

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer

5 July 2024

27

1 reference

https://api.crossref.org/works/10.1097/ICU.0B013E32833F0085

5 July 2024

Identifiers

1 reference

23 August 2017

1 reference